Abstract: The subject matter of the invention is a detector system for detecting magnetic bodies in the human organism, which comprises at least two sensor assemblies, wherein each sensor assembly has one, two or three anisotropic magnetic resistance sensors, of which the axes of weak magnetization point in different directions in pairs, and each sensor assembly has a spacing of 0.5 to 50 cm from the sensor assembly or the other sensor assemblies, and at least two sensor assemblies are tilted at an angle of 0 to 45° with respect to one another, and in addition a method for detecting the magnetic flux produced by a magnetic body in the human organism, and the use of the detector system according to the invention for detecting swallowed magnetic bodies and the disintegration of the same in the digestive system.

Abstract: Process for preparing (meth)acrylates of the formula (I) CH2?C(R1)—CO—O—R2??(I) in which R1 is hydrogen or methyl and R2 is a saturated or unsaturated, linear or branched, aliphatic or cyclic alkyl radical having 6 to 22 carbon atoms, or a (C6-C14)-aryl-(C1-C8)-alkyl radical; by reacting a (meth)acrylate of the formula II CH2?C(R1)—CO—OR3??(II) with an alcohol of the formula (III) HO—R2??(III) in the presence of an amount of a suitable catalyst which catalyzes the reaction and of an amount of a phenolic polymerization inhibitor or a combination of two or more phenolic polymerization inhibitors which is sufficient to inhibit undesired polymerization; the reaction being undertaken with input or introduction into the reaction mixture resulting from the reaction of an amount of oxygen or of an oxygenous gas mixture sufficient to inhibit undesired polymerization, and the process is characterized in that the specific total oxygen input is less than or equal to 1.

Abstract: A block-copolymer containing at least two different blocks wherein block A contains (meth)acrylate monomers the copolymer having a glass transition temperature of less than 15° C., block B contains (meth)acrylate monomers the copolymer having a glass transition temperature of more than 25° C. being free of thio-containing substances in the polymer chain, characterized in that one block contains at least one photoinitiator chemically bound to the chain.

Abstract: The invention relates to a coating composition suitable for the coating of pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process, wherein the core of the core/shell polymer composition is formed by a water-insoluble, cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer.

Abstract: The present invention relates to a process for preparing alpha-hydroxycarboxylic esters from the alcoholysis of alpha-hydroxycarboxam ides in the gas phase, characterized in that the conversion is effected in the presence of water.

Abstract: The invention relates to a process for preparing methacrylic esters of hydroxyl-functional benzophenones and to their use. Methacrylated benzophenones (benzophenone (meth)acrylates) can be prepared in high purity by the process of the invention, in a simple way and in a high yield.

Abstract: The invention relates to a process for the production of mould-foamed poly(meth)acrylimide (P(M)I) cores, in particular of polymethacrylimide (PMI) cores, which can be used by way of example in automobile construction or aircraft construction. A feature of this process is that polymer granules or polymer powder preheated under pressure are moreover charged under pressure to a compression mould where they are foamed with depressurization. In particular, a feature of the process is that it optionally uses a preferably two-shell compression mould for the heating and also for the cooling of the granules and, respectively, the rigid foam core formed therefrom.

Abstract: The present invention relates to a process for preparing alkyl methacrylates and their conversion products which can be used in a multitude of chemical synthesis processes which can lead to a wide variety of different further processing products, and to an apparatus for performing this process.

Abstract: The present invention relates to a method for the continuous inline production of coated polymeric substrates or laminates and also to an apparatus for implementing this method.

Abstract: The present invention describes a method of removing ammonia from alcoholic solution in the presence of carbonic acid compounds while avoiding fouling by supplying the solution to be separated to the upper part of a distillation column and adjusting the temperature at the introduction point such that the ammonium salts of the carbonic acid compound in question are soluble in the in question at the top of the distillation column under the operating conditions.

Abstract: The present invention relates to a process for preparing methyl methacrylate by a direct oxidative esterification of methacrolein with oxygen and methanol, which is conducted in the liquid phase at a pressure of 2 to 100 bar with a gold catalyst. According to the invention, the liquid phase is withdrawn continuously from the reactor and optionally enriched with oxygenous gas, the pH, after the withdrawal, is adjusted to a pH between 5 and 9 by means of addition of a basic solution and this liquid phase is conducted back into the reactor again to an extent of at least 50%.

Abstract: The present invention concerns regulating the water content in a process for production of methacrolein. Methacrolein is used in chemical synthesis particularly as an intermediate for production of methacrylic acid, methyl methacrylate or else of active, aroma or flavor chemicals. The present invention is particularly concerned with regulating the water content in a process for production of methacrolein from formaldehyde and propionaldehyde via a Mannich condensation.

Abstract: The invention relates to a process for the production of mould-foamed poly(meth)acrylimide (P(M)I) cores, in particular of polymethacrylimide (PMI) cores, which can be used by way of example in automobile construction or aircraft construction. A feature of this process is that polymer granules or polymer powder are charged to a compression mould where they are foamed. A particular feature of the process is that said two-shell compression mould has, respectively on both sides, a cavity that conforms to the shape and which serves for both the heating and the cooling of the granules and, respectively, of the rigid foam core produced therefrom.

Abstract: The present invention provides a solid dosage form including an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein the inner coating includes a partially neutralized anionic polymeric material, and at least a carboxylic acid having 2 to 16 carbon atoms the salts thereof or mixtures of the acid and its salt; wherein the outer coating includes an anionic polymeric material which is less or not at all neutralized than the material of the inner coating.

Abstract: The present invention relates to a process for preparing methyl methacrylate by direct oxidative esterification of methacrolein and the preparation of methacrolein. It is a feature of this novel process that it was possible to distinctly increase the yield and the efficiency of the process compared to the prior art through a sequence of different distillation steps.

Abstract: The present invention relates to a process for producing transparent polymeric films or plastics moldings of particularly high chemical resistance, having more particularly a very good resistance towards oil-in-water and water-in-oil emulsions, and of high optical quality.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0. characterized in that the coating layer further contains 110 to 250% by weight, calculated on dry weight of the polymer mixture, of a non-porous inert lubricant and the is present in an amount of at least 60% by weight calculated on the weight of core.

Abstract: The present invention claims a process for preparing high-purity glycerol dimethacrylate comprising <500 ppm of glycidyl methacrylate, characterized in that an aftertreatment with acidic adsorbent is effected.

Abstract: A method for the reversible crosslinking of, for example, adhesives or coating materials, and a composition stable on storage at room temperature for implementing the crosslinking reaction. The reversible crosslinking method allows very rapid crosslinking even at a low first temperature, and undoing of the crosslinks at higher temperatures, thereby recovering thermoplastic processability and, for example, allowing the originally bonded substrates to be parted from one another again easily. A particular aspect is that a plurality of cycles of crosslinking and undoing of the crosslinks are possible with the present system. A feature of the system used for the reversible crosslinking is that it contains two components, A and B, where component A is a compound having at least two protected dithioester functionalities, preferably cyanodithioester functionalities, and component B is a compound having at least two diene functionalities.

Abstract: The invention refers to a pharmaceutical or nutraceutical composition, comprising a) a core, comprising a pharmaceutical or a nutraceutical active ingredient, b) an inner coating layer comprising one or more salts of alginic acid and c) an outer coating layer comprising one or more water-insoluble polymers or copolymers and one or more water-soluble polymers, selected from the group of water soluble celluloses, polyvinyl pyrrolidones or polyethylene glycols or any combinations thereof. wherein the ratio by weight of the amount of the one or more salts of alginic acid in the inner coating layer to the amount of the one or more water-insoluble polymers or copolymers in outer coating layer is from 0.6 to less than 2.5:1.